Crinetics Pharmaceuticals, Inc.

NasdaqGS:CRNX Stock Report

Market Cap: US$8.8b

Crinetics Pharmaceuticals Management

Management criteria checks 2/4

Crinetics Pharmaceuticals' CEO is R. Struthers, appointed in Dec 2008, has a tenure of 17.58 years. total yearly compensation is $11.63M, comprised of 6.2% salary and 93.8% bonuses, including company stock and options. directly owns 1.14% of the company’s shares, worth $101.01M. The average tenure of the management team and the board of directors is 5.1 years and 5.8 years respectively.

Key information

R. Struthers

Chief executive officer

US$11.6m

Total compensation

CEO salary percentage6.18%
CEO tenure17.6yrs
CEO ownership1.1%
Management average tenure5.1yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Narrative Update • Jul 10

CRNX: Takeover Offer And Delayed Rival Entry Will Shape Endocrine Outlook

Crinetics Pharmaceuticals' analyst fair value estimate has been trimmed from $97 to $90 as analysts recalibrate expectations around the $85 per share cash acquisition by Vertex Pharmaceuticals and the cluster of rating downgrades to Hold or Neutral that now anchor views closer to the agreed deal price. Analyst Commentary Analysts covering Crinetics Pharmaceuticals are now largely treating the stock as a merger arbitrage situation, with ratings concentrated around Hold or Neutral and price targets aligning closely with the agreed US$85 per share cash offer from Vertex Pharmaceuticals.
Seeking Alpha • Jul 07

Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know

Summary Vertex Pharmaceuticals Incorporated acquires Crinetics Pharmaceuticals, Inc. for $85/share, valuing the deal at ~$10bn to diversify beyond its cystic fibrosis franchise. CRNX brings PALSONIFY, a newly approved oral acromegaly therapy with blockbuster potential, and atumelnant, a Phase 3 CAH candidate, strengthening VRTX's rare disease portfolio. VRTX expects Crinetics' assets to deliver up to $5bn peak annual revenues, supporting a path toward five blockbuster products and ~$20bn revenues by 2030. The CRNX acquisition is funded by cash and debt, leveraging VRTX's strong balance sheet, with anticipated deal closure in Q3 2026 and minimal near-term financial strain. Read the full article on Seeking Alpha
Narrative Update • Jun 26

CRNX: Delayed Rival Entry Will Support Early Acromegaly Launch Execution

The analyst fair value estimate for Crinetics Pharmaceuticals has been revised from $108.00 to $97.00, with analysts citing a reset to more moderate revenue growth, a slightly higher discount rate, and updated assumptions around future margins and P/E multiples, even as they highlight potential benefits from delayed competitive pressure in acromegaly following the Oclaiz complete response letter. Analyst Commentary Recent research coverage on Crinetics Pharmaceuticals highlights a mix of valuation resets and constructive views on the launch setup for Palsonify in acromegaly.
Analysis Article • Jun 19

Crinetics Pharmaceuticals (CRNX) Stock Could Be 56.5% Undervalued After ENDO 2026 Data

Crinetics Pharmaceuticals (CRNX) is back in focus after presenting extensive new data at the Endocrine Society’s 2026 meeting, covering both its approved acromegaly drug PALSONIFY and its investigational ACTH receptor antagonist atumelnant. See our latest analysis for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals’ recent ENDO 2026 updates have arrived alongside a mixed share price picture, with a 7 day share price return of 6.98% contrasting with a year to date decline of 23.24%, while...
Analysis Article • May 13

Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%

Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) shareholders will have a reason to smile today, with the analysts...
Seeking Alpha • Jan 02

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness

Summary Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, setting a PDUFA date of 09/24/2025. Crinetics is preparing for a fall 2025 launch of paltusotine, engaging with payers and endocrinologists to ensure broad patient access and formulary placement. Despite its valuation, Crinetics' advancements in acromegaly treatment and strong Wall Street backing make it a hold and potential acquisition on pullbacks. Read the full article on Seeking Alpha
Seeking Alpha • Aug 12

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Summary Paltusotine in the treatment of acromegaly is Crinetics lead therapy with NDA filing planned in H2 2024. Crinetics has no approved drug and its lead therapy will face significant competition once approved. Investors should be aware of the high-risk nature of investing in Crinetics Pharmaceuticals. Read the full article on Seeking Alpha
Seeking Alpha • May 23

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

Summary Positive data released from 4 patients from phase 2 study that took Atumelnant for congenital adrenal hyperplasia, showing reductions in key biomarkers of A4 and 17-OHP. An NDA submission of Paltusotine for the treatment of patients with Acromegaly expected in the 2nd half of 2024. Additional results from phase 2 open-label study, using Atumelnant for patients with CAH, to be presented at ENDO Conference on June 3rd 2024 at 12:00 to 1:30 p.m. ET. Pending positive talks with FDA, possible initiation of phase 3 study using Paltusotine for the treatment of patients with Carcinoid Syndrome by end of 2024. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has R. Struthers's remuneration changed compared to Crinetics Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$496m

Dec 31 2025US$12mUS$719k

-US$465m

Sep 30 2025n/an/a

-US$423m

Jun 30 2025n/an/a

-US$370m

Mar 31 2025n/an/a

-US$328m

Dec 31 2024US$11mUS$654k

-US$298m

Sep 30 2024n/an/a

-US$278m

Jun 30 2024n/an/a

-US$259m

Mar 31 2024n/an/a

-US$235m

Dec 31 2023US$6mUS$614k

-US$215m

Sep 30 2023n/an/a

-US$199m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$175m

Dec 31 2022US$6mUS$590k

-US$164m

Sep 30 2022n/an/a

-US$150m

Jun 30 2022n/an/a

-US$136m

Mar 31 2022n/an/a

-US$119m

Dec 31 2021US$4mUS$567k

-US$108m

Sep 30 2021n/an/a

-US$98m

Jun 30 2021n/an/a

-US$89m

Mar 31 2021n/an/a

-US$79m

Dec 31 2020US$4mUS$544k

-US$74m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$63m

Mar 31 2020n/an/a

-US$59m

Dec 31 2019US$4mUS$542k

-US$50m

Compensation vs Market: R.'s total compensation ($USD11.63M) is above average for companies of similar size in the US market ($USD8.42M).

Compensation vs Earnings: R.'s compensation has increased whilst the company is unprofitable.

CEO

R. Struthers (64 yo)

17.6yrs
Tenure
US$11,628,959
Compensation

Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...

Leadership Team

NamePositionTenureCompensationOwnership
R. Struthers
Founder17.6yrsUS$11.63m1.14%
$ 101.0m
Stephen Betz
Co-Founder & Chief Scientific Officer18.5yrsUS$3.83m0.054%
$ 4.8m
Tobin Schilke
Chief Financial Officer1.4yrsUS$4.45m0.0067%
$ 595.9k
Kea Lingo
Chief Information Officer1.3yrsno datano data
Gayathri Diwakar
Head of Investor Relationsno datano datano data
Garlan Adams
Chief Legal Officer & Corporate Secretary5.1yrsno datano data
Natalie Badillo
Head of Corporate Communicationsno datano datano data
Adriana Cabre
Chief Human Resources Officer6.2yrsno datano data
Alan Krasner
Chief Endocrinologist8.1yrsUS$2.16mno data
Kevin Capps
Head of Intellectual Propertyno datano datano data
Chris Robillard
Chief Business Officer4.3yrsno datano data
Robert Cuddihy
Senior Vice President of Medical Affairs2.2yrsno datano data
5.1yrs
Average Tenure
61.5yo
Average Age

Experienced Management: CRNX's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
R. Struthers
Founder17.7yrsUS$11.63m1.14%
$ 101.0m
Wendell Wierenga
Independent Chairman of the Board10.8yrsUS$528.62k0.11%
$ 9.7m
Matthew Fust
Independent Director8.4yrsUS$498.59k0.022%
$ 1.9m
Camille Bedrosian
Independent Director5.8yrsUS$500.47k0.015%
$ 1.4m
Beverly M. Biller
Member of Scientific Advisory Boardno datano datano data
Rogerio Vivaldi Coelho
Independent Director4.5yrsUS$507.34k0.013%
$ 1.1m
Weston Nichols
Independent Director8.4yrsUS$493.84k0.015%
$ 1.4m
Stephanie Okey
Independent Director7yrsUS$500.47k0.0061%
$ 535.9k
Caren Deardorf
Independent Director4.3yrsUS$485.47k0.015%
$ 1.4m
Martin Heinrich Reincke
Member of Scientific Advisory Board4.3yrsno datano data
John Newell-Price
Member of Scientific Advisory Board4.3yrsno datano data
William Young
Member of Scientific Advisory Board4.3yrsno datano data
5.8yrs
Average Tenure
63yo
Average Age

Experienced Board: CRNX's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/26 02:45
End of Day Share Price 2026/07/24 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Crinetics Pharmaceuticals, Inc. is covered by 22 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Joshua SchimmerCantor Fitzgerald & Co.
David LebowitzCitigroup Inc